EMEA-002242-PIP01-17
Key facts
| Active substance |
Tucatinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0036/2018
|
| PIP number |
EMEA-002242-PIP01-17
|
| Pharmaceutical form(s) |
Tablet
|
| Condition(s) / indication(s) |
Treatment of breast malignant neoplasms
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Cascadian Therapeutics Luxembourg S.A.R.L.
Tel. +1 2068012100
E-mail: HER2CLIMBinquiries@cascadianrx.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|